Every 8-K that Orgenesis Inc (ORGS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ORGS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORGS filings page.
Orgenesis Inc. reported that stockholders approved a major change to its capital structure at a special meeting on May 27, 2026. They authorized an increase in total common shares from 14,583,333 to 150,000,000, and the related charter amendment became effective when filed in Nevada on June 2, 2026.
Stockholders also approved a share issuance proposal tied to a Convertible Loan Agreement dated September 10, 2025 among Theracell Laboratories IKE, Orgenesis Inc., and Alpha Prosperity Fund SPC, and ratified Kesselman & Kesselman C.P.A.s (a PwC member firm) as independent auditors for 2025. The filing reiterates that Orgenesis’ stock is no longer listed on Nasdaq and currently trades on the OTC Expert Market.
Orgenesis Inc. reported issuing an Alpha Warrant to Alpha Prosperity Fund SPC in connection with a previously agreed convertible loan and credit facility. The warrant relates to the first $1,000,000 drawdown under a $1,000,000 convertible loan and $10,000,000 credit facility and is exercisable for 3,289,490 shares of common stock for an aggregate exercise price of $250,000 over three years. The company states that the Alpha Warrant and the shares issuable upon exercise were issued without registration under the Securities Act, relying on the Section 4(a)(2) exemption for transactions not involving a public offering.
Orgenesis Inc. entered into a Convertible Loan Agreement through its subsidiary Theracell Laboratories IKE with Alpha Prosperity Fund SPC. The lender is providing an initial $1,000,000 loan at a simple interest rate of 10% per year, maturing in 36 months. Theracell may fully prepay during the first 30 days; afterward any repayment needs lender approval.
After 30 days and until maturity, the lender can choose to convert the outstanding amount into equity of either Orgenesis or Theracell so that it would hold up to 80% of the applicable company’s outstanding share capital, with any conversion into Orgenesis shares requiring shareholder approval. The agreement also grants a warrant to buy 15% of fully diluted share capital of Orgenesis or Theracell for a total exercise price of $250,000, plus additional similar warrants with each extra $1,000,000 draw. The facility provides up to $10,000,000, under which $7,083,857 has been drawn and $6,083,857 of prior debt was repaid. After 30 days and required approvals, the lender may appoint three directors to Orgenesis’ board.